RT Journal Article
SR Electronic
T1 Acceptance of an Mpox Vaccine in the Democratic Republic of the Congo
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.15.24311971
DO 10.1101/2024.08.15.24311971
A1 Petrichko, Skylar
A1 Kindrachuk, Jason
A1 Nkamba, Dalau
A1 Halbrook, Megan
A1 Merritt, Sydney
A1 Kalengi, Handdy
A1 Kamba, Leonard
A1 Beya, Michael
A1 Hoff, Nicole A.
A1 Luhata, Christophe
A1 Kaba, Didine K.
A1 Rimoin, Anne W.
YR 2024
UL http://medrxiv.org/content/early/2024/09/04/2024.08.15.24311971.abstract
AB We report general acceptance of an mpox vaccine (61.0%) in the Democratic Republic of the Congo (n = 5226) with higher acceptance among healthcare workers and respondents in historic mpox-endemic regions. These data highlight the need for increased community engagement and sensitization before widespread deployment of mpox vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project or effort depicted is funded by the Task Force for Global Health (TFGH) under Grant # 20234052:1. The content of the information does not necessarily reflect the position or the policy of TFGH, and no official endorsement should be inferred.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approvals were provided by the Kinshasa School of Public Health (IRB# ESP/CE/188/2023), and a public health response activity designation by UCLA and Task Force for Global Health.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.